nach oben

Current Sleep Medicine Reports

Erschienen in:

01.12.2016 | Women and Sleep (A Wolfson and K Sharkey, Section Editors)

Sleep Medications and Women: a Review of Issues to Consider for Optimizing the Care of Women with Sleep Disorders

verfasst von: Andrew Krystal, Hrayr Attarian

Erschienen in: Current Sleep Medicine Reports | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Certain medications exhibit sex-specific pharmacological profiles. It is, therefore, imperative to understand their unique pharmacokinetic properties to optimize women’s health. Two such medications that are commonly used in sleep medicine are zolpidem and modafinil/armodafinil. The first is a sedative hypnotic while the latter, in both its incarnations, a wake-promoting agent. The slower clearance of these medications and higher serum concentrations after dosing in women are independent of weight and have to do with the impact of estrogen on the liver enzymes involved in the metabolism of these medications. Below, we summarize and discuss the data that is available on the sex-specific dosing of zolpidem, which in women, by FDA recommendations, is half of what is recommended in men. We also discuss the reasons behind the interaction of hormonal birth control and modafinil/armodafinil and rate of contraceptive failure when hormonal birth control is used with this wake-promoting agent.

MacFarlane J, Morin CM, Montplaisir J. Hypnotics in insomnia: the experience of zolpidem. Clin Ther. 2014;36(11):1676–701.CrossRefPubMed

Neubauer DN. ZolpiMist: a new formulation of zolpidem tartrate for the short-term treatment of insomnia in the US. Nat Sci Sleep. 2010;2:79–84.CrossRefPubMedPubMedCentral

Roehrs TA et al. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol. 2012;26(8):1088–95.CrossRefPubMed

Poceta JS. Zolpidem ingestion, automatisms, and sleep driving: a clinical and legal case series. J Clin Sleep Med. 2011;7(6):632–8.PubMedPubMedCentral

Licata SC et al. Modest abuse-related subjective effects of zolpidem in drug-naive volunteers. Behav Pharmacol. 2011;22(2):160–6.CrossRefPubMedPubMedCentral

Hwang TJ et al. Risk predictors for hypnosedative-related complex sleep behaviors: a retrospective, cross-sectional pilot study. J Clin Psychiatry. 2010;71(10):1331–5.CrossRefPubMed

Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994;55(5):192–9.PubMed

Roth T, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep. 1995;18(4):246–51.PubMed

Wisor JP, Eriksson KS. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience. 2005;132(4):1027–34.CrossRefPubMed

10.

US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol. 1998;43(1):88–97.CrossRef

11.

Black JE et al. The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. J Clin Sleep Med. 2010;6(5):458–66.PubMedPubMedCentral

12.

Darwish M, Bond M, Ezzet F. Armodafinil and modafinil in patients with excessive sleepiness associated with shift work disorder: a pharmacokinetic/pharmacodynamic model for predicting and comparing their concentration-effect relationships. J Clin Pharmacol. 2012;52(9):1328–42.CrossRefPubMed

13.

Czeisler CA et al. Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med. 2005;353(5):476–86.CrossRefPubMed

14.

Inoue Y, Takasaki Y, Yamashiro Y. Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study. J Clin Sleep Med. 2013;9(8):751–7.PubMedPubMedCentral

15.

Morgan PT et al. Modafinil and sleep architecture in an inpatient-outpatient treatment study of cocaine dependence. Drug Alcohol Depend. 2016;160:49–56.CrossRefPubMed

16.

Krishnan R, Chary KV. A rare case modafinil dependence. J Pharmacol Pharmacother. 2015;6(1):49–50.CrossRefPubMedPubMedCentral

17.

Kuan YC et al. Effects of modafinil and armodafinil in patients with obstructive sleep apnea: a meta-analysis of randomized controlled trials. Clin Ther. 2016;38(4):874–88.CrossRefPubMed

18.

Greenblatt DJ et al. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J Pharmacol Exp Ther. 2000;293(2):435–43.PubMed

19.

Dijk DJ et al. Sex differences and the effect of gaboxadol and zolpidem on EEG power spectra in NREM and REM sleep. J Psychopharmacol. 2010;24(11):1613–8.CrossRefPubMed

20.

Greenblatt DJ et al. Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration. J Clin Pharmacol. 2014;54(3):282–90.CrossRefPubMed

21.

Olubodun JO et al. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br J Clin Pharmacol. 2003;56(3):297–304.CrossRefPubMedPubMedCentral

22.

Verster JC, Roth T. Gender differences in highway driving performance after administration of sleep medication: a review of the literature. Traffic Inj Prev. 2012;13(3):286–92.CrossRefPubMed

23.

Peer CJ, Strope JD, Beedie S, Ley AM, Holly A, Calis K, et al. Alcohol and aldehyde dehydrogenases contribute to sex-related differences in clearance of zolpidem in rats. Front Pharmacol. 2016;7:260. doi:10.3389/fphar.2016.00260. eCollection 2016.CrossRefPubMedPubMedCentral

24.

FDA. FDA drug safety communication: risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist) 2013.

25.

Robertson Jr P, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003;42(2):123–37.CrossRefPubMed

26.

Darwish M et al. Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults. Clin Drug Investig. 2014;34(10):691–9.CrossRefPubMed

27.

Goss AJ et al. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013;74(11):1101–7.CrossRefPubMed

28.

Tao G et al. Population pharmacokinetics of modafinil in Chinese Han, Mongolian, Korean, Uygur, and Hui healthy subjects determined by nonlinear mixed-effects modeling. Ther Drug Monit. 2010;32(2):189–93.PubMed

29.

Somner J et al. Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2004;89(1):344–51.CrossRefPubMed

30.

Unknown. Guttmacher Institute fact sheet: contraceptive use in the United States. 2015 October 2015 [cited 2016 June 7th].

31.

Mosher W, Jones J. Use of contraception in the United States: 1982–2008. Vital Health Stat. 2010;23(29):1–37.

32.

Robertson Jr P et al. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. Clin Pharmacol Ther. 2002;71(1):46–56.CrossRefPubMed

33.

Davies M, Wilton L, Shakir S. Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: results of a modified prescription-event monitoring study. Drug Saf. 2013;36(4):237–46.CrossRefPubMed

34.

Darwish M et al. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin Drug Investig. 2009;29(9):613–23.CrossRefPubMed

35.

Mayer G et al. Modafinil in the treatment of idiopathic hypersomnia without long sleep time—a randomized, double-blind, placebo-controlled study. J Sleep Res. 2015;24(1):74–81.CrossRefPubMed

36.

Asano M, Finlayson ML. Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication. Mult Scler Int. 2014;2014:798285.PubMedPubMedCentral

Titel: Sleep Medications and Women: a Review of Issues to Consider for Optimizing the Care of Women with Sleep Disorders
verfasst von: Andrew Krystal
Hrayr Attarian
Publikationsdatum: 01.12.2016
Verlag: Springer International Publishing
Erschienen in: Current Sleep Medicine Reports / Ausgabe 4/2016
Elektronische ISSN: 2198-6401
DOI: https://doi.org/10.1007/s40675-016-0060-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

The Relationship of Suicidal Thoughts and Behaviors to Sleep Disturbance: a Review of Recent Findings

How Adult Caregiving Impacts Sleep: a Systematic Review

A Quarter Century of Research Progress Leads to Answers and New Questions for Women’s Sleep Health

Sleep-Disordered Breathing in Pregnancy

Cognitive Behavioural Therapy for Insomnia in Psychiatric Disorders